GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Nautilus Biotechnology
Nautilus Biotechnology is developing a platform for proteome (protein) analysis. Its stock price is a venture bet on a revolution in biological research. The chart reflects the long road to commercialization and the high need for funding.
Share prices of companies in the market segment - Dna
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for the analysis and quantification of proteins in the human body on a large scale. We classify this as part of the "DNA Technologies" sector (broadly defined). The graph below illustrates the dynamics of this segment.
Broad Market Index - GURU.Markets
Nautilus Biotechnology is developing a platform for analyzing the proteome—the complete set of proteins in a cell—which should accelerate drug discovery. As a pioneer, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Nautilus's performance.
Change in the price of a company, segment, and market as a whole per day
NAUT - Daily change in the company's share price Nautilus Biotechnology
Nautilus Biotechnology's daily share price fluctuations reflect the high volatility inherent in companies at the intersection of biotech and IT. This metric measures the company's sensitivity to progress in developing its proteome analysis platform, serving as a risk assessment element.
Daily change in the price of a set of shares in a market segment - Dna
Nautilus Biotechnology's daily share price fluctuations reflect the high volatility inherent in companies at the intersection of biotech and IT. This metric measures the company's sensitivity to progress in developing its proteome analysis platform, serving as a risk assessment element.
Daily change in the price of a broad market stock, index - GURU.Markets
Nautilus Biotechnology is developing a revolutionary protein analysis platform, aiming to transform biomedical research. The company's shares are a bet on a future scientific breakthrough. Their high, speculative volatility is part of the dynamics of the innovation sector, influencing the entire market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Nautilus Biotechnology
Nautilus Biotechnology's year-to-date performance is a story about the development of a new platform for proteome analysis. Its market capitalization over the next 12 months depends on progress in developing its instrument, which promises to identify and measure proteins on an unprecedented scale. A successful launch will be a fundamental breakthrough for biomedical research.
Annual dynamics of market capitalization of the market segment - Dna
Nautilus Biotechnology, Inc. is a biotech company developing a proteome analysis platform. Its technology promises to accelerate scientific discovery. This chart illustrates how its innovative yet capital-intensive model and reliance on future commercialization impact its volatile performance in the sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nautilus, with its protein analysis platform, is a speculative bet on the future of medicine. Its stock price isn't tied to the economy, but rather driven by scientific breakthroughs and partnerships. The chart tells the story of investors' faith that its technology will revolutionize diagnostics and drug discovery.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Nautilus Biotechnology
Nautilus Biotechnology is developing a platform for proteome (protein cluster) analysis. While in the development stage, its monthly valuation is based on technological potential. News of key development milestones and potential future partnerships are key drivers.
Monthly dynamics of market capitalization of the market segment - Dna
Nautilus Biotechnology, Inc. is developing a proteome (protein assay) platform capable of identifying and measuring billions of individual protein molecules. The dynamics of its sector, shown in the graph, reflect scientific progress. Against this backdrop, one can appreciate how its breakthrough technology can accelerate drug and biomarker discovery.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Nautilus Biotechnology develops a protein analysis platform, making its stock a bet on a future breakthrough in biotechnology. Its stock moves based on news about the technology's development, not the market. The chart demonstrates the volatility typical of companies that promise to change the industry but don't yet have revenue.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Nautilus Biotechnology
Nautilus Biotechnology, a company developing a platform for proteome (protein) analysis, is at the forefront of biotechnology. Its weekly stock price is highly volatile, driven by news of technological advances and partnerships, reflecting expectations for a revolution in biological research.
Weekly dynamics of market capitalization of the market segment - Dna
Nautilus Biotechnology aims to revolutionize proteomics by analyzing proteins at scale. This chart will show how investors view its breakthrough potential compared to the broader biotech sector, helping to understand whether it's at the forefront of the industry or moving alongside it.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Nautilus Biotechnology is developing a protein analysis platform. As a company at the cutting edge of science, its shares can be highly volatile. The chart will show whether they are prone to market movement, reflecting investor appetite for risky technology plays.
Market capitalization of the company, segment and market as a whole
NAUT - Market capitalization of the company Nautilus Biotechnology
The Nautilus Biotechnology stock chart is a financial bet on a revolution in proteomics. The market cap of this company, which is developing a platform for protein analysis on an unprecedented scale, reflects faith in its technology. Its volatility reflects the hope that proteome analysis will become as important to medicine as genome analysis.
NAUT - Share of the company's market capitalization Nautilus Biotechnology within the market segment - Dna
Nautilus Biotechnology's stake in the DNA analysis sector is a bet on technological breakthroughs. The company is developing a platform for protein analysis on an unprecedented scale. Its market share reflects not current revenues, but investors' belief in its ability to revolutionize biomedical research.
Market capitalization of the market segment - Dna
Nautilus Biotechnology is developing a platform for protein analysis on an unprecedented scale. The chart below shows the overall market capitalization of the entire biotech sector. Its dynamics reflect investors' belief that proteomics will be the next big revolution after genomics.
Market capitalization of all companies included in a broad market index - GURU.Markets
Nautilus Biotechnology is developing a platform for proteome (protein) analysis that promises to revolutionize biology and medicine. Its market capitalization is a bet on this breakthrough. The chart below shows the economic weight of companies creating scientific tools.
Book value capitalization of the company, segment and market as a whole
NAUT - Book value capitalization of the company Nautilus Biotechnology
Nautilus Biotechnology's book value is its equity and prototype protein analysis equipment. The chart below shows the financial and scientific resources allocated to the creation of a new technological platform. This is a story of capital being converted into cutting-edge scientific equipment.
NAUT - Share of the company's book capitalization Nautilus Biotechnology within the market segment - Dna
Nautilus Biotechnology develops a platform for proteome (protein) analysis. Its business focuses on creating unique and complex scientific instruments. The share chart shows how it invests in R&D and manufacturing capacity to develop its innovative physics technology.
Market segment balance sheet capitalization - Dna
Nautilus Biotechnology is developing a proteome analysis platform. Its assets are not factories, but unique instrument prototypes and laboratories. This is capital-intensive R&D. The graph will show how "lightweight" the entire nascent proteomics sector is compared to the giants of the genomics industry.
Book value of all companies included in the broad market index - GURU.Markets
Nautilus Biotechnology's assets represent capital invested in creating a platform for analyzing individual protein molecules on a massive scale. Its book value reflects its investment in a technology that could revolutionize biomedicine, just as DNA sequencing revolutionized genetics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Nautilus Biotechnology
Nautilus Biotechnology is developing a platform for proteome (protein assemblage) analysis on an unprecedented scale. The company has no commercial product. Its market capitalization is a bet that its technology will revolutionize biology and medicine. The chart reflects investor faith in its long-term vision, not its current assets.
Market to book capitalization ratio in a market segment - Dna
Nautilus Biotechnology is developing a platform for proteome (protein analysis) that could revolutionize medicine. It's an early-stage company, and its valuation is based on expectations. The chart shows the wide gap between market valuation and book value, typical of breakthrough technologies.
Market to book capitalization ratio for the market as a whole
Nautilus Biotechnology is developing a platform for protein analysis on an unprecedented scale. The chart shows how the market values the company, which is creating a "tool for future discoveries." Its market capitalization is based not on its current assets, but on investors' belief that its technology will become fundamental to the biopharmaceutical industry.
Debts of the company, segment and market as a whole
NAUT - Company debts Nautilus Biotechnology
Nautilus Biotechnology is developing a platform for proteome (protein assemblies) analysis that could revolutionize biomedical research. This is a capital-intensive undertaking. This chart shows how the company is raising significant funding to support its ambitious R&D goals toward commercialization.
Market segment debts - Dna
Nautilus Biotechnology is developing a platform for proteome (protein assemblies) analysis on an unprecedented scale. This could revolutionize biomedical research. The chart illustrates the financial landscape for the biotech sector, which is driving Nautilus's massive capital investment to develop its complex and breakthrough technology platform.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Nautilus Biotechnology
Nautilus Biotechnology is developing a protein analysis platform, aiming to revolutionize biomedical research. Developing such a complex technology requires significant capital investment. This chart illustrates the company's reliance on external funding. It reflects the financial risks at a stage before the company generates significant revenue.
Market segment debt to market segment book capitalization - Dna
Nautilus's development of protein analysis platforms could accelerate drug development. This chart shows the overall debt burden in the Life Sciences sector. It allows one to assess how the financial model of a company developing unique equipment compares to the industry average, which is dominated by established manufacturers.
Debt to book value of all companies in the market
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for protein analysis. Developing such breakthrough technologies requires significant R&D capital. The chart shows how this research-intensive company's debt compares to mature and profitable sectors of the economy.
P/E of the company, segment and market as a whole
P/E - Nautilus Biotechnology
This chart shows the valuation of Nautilus Biotechnology, a company developing a protein analysis platform. For a company at the intersection of biotech and IT, its value is determined by investors' belief in its ability to revolutionize proteomics. This metric reflects long-term scientific potential, not current profits.
P/E of the market segment - Dna
This chart shows the average valuation for the biotechnology sector, specifically research tool development companies like Nautilus Biotechnology. This metric reflects investor confidence in technological breakthroughs and serves as a benchmark for understanding how the market views Nautilus's potential to revolutionize protein analysis.
P/E of the market as a whole
Nautilus Biotechnology is developing a platform for proteome analysis (the sum of all proteins) that could accelerate drug discovery and diagnostics. This is a bet on a new technological paradigm in biology. This chart reflects the market's faith in breakthrough technologies and helps us understand whether Nautilus is valued as a company capable of creating a new standard in research, similar to DNA sequencing.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Nautilus Biotechnology
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for protein analysis on an unprecedented scale. The company's future depends on the successful commercialization of its sophisticated technology. This graph reflects investors' high, yet speculative, expectations for a breakthrough in protein analysis that could revolutionize drug development and diagnostics.
%20P%2FE%20Nautilus%20Biotechnology&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Nautilus-Biotechnology&v=1772647445093 "Chart of the company's future (projected) P/E Nautilus Biotechnology")
Future (projected) P/E of the market segment - Dna
Nautilus Biotechnology aims to revolutionize proteomics—the study of proteins. The company is developing a platform for analyzing millions of individual protein molecules, which could accelerate drug discovery. This chart reflects industry expectations, helping to gauge how highly the market values this ambitious, yet unrealized, technological breakthrough.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Dna&v=1772647445125 "Future (projected) P/E graph of the market segment - Dna")
Future (projected) P/E of the market as a whole
Nautilus Biotechnology is developing a platform for analyzing the proteome (the body's protein composition) on an unprecedented scale. This could revolutionize diagnostics and drug development. This graph of overall expectations demonstrates the willingness of investors to invest in breakthrough scientific technologies. Market optimism is essential for funding such ambitious and long-term projects.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772647445188 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Nautilus Biotechnology
Nautilus Biotechnology is developing a protein analysis (proteomics) platform that could revolutionize biomedical research. This chart reflects the financial costs of developing this breakthrough technology. Profitability is a long-term goal, and current figures demonstrate the investment in the development and commercialization of this complex system.
Profit of companies in the market segment - Dna
authID Inc. provides biometric identity authentication solutions. The company's profitability is growing alongside the need for secure verification in the digital world. This chart shows how the rise of online fraud and the need for data protection are driving ever-increasing demand for reliable identification technologies, supporting the sector's profitability.
Overall market profit
Nautilus Biotechnology is developing a platform for the large-scale analysis of individual protein molecules, aiming to revolutionize proteomics. The company is at the intersection of biology and big data. Its success depends on technological breakthroughs that could accelerate drug development and diagnostics, fundamental to the future of healthcare.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Nautilus Biotechnology
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for protein analysis at an unprecedented scale. The company's revenue projections during the development stage are long-term and speculative. This chart reflects analysts' confidence in Nautilus's technological breakthrough and its potential impact on drug discovery and diagnostics.
%20profit%20of%20the%20company%20Nautilus%20Biotechnology&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Nautilus-Biotechnology&v=1772647445474 "Graph of future (projected) profit of the company Nautilus Biotechnology")
Future (predicted) profit of companies in the market segment - Dna
Nautilus Biotechnology is developing a platform for analyzing the proteome—the sum of all proteins in a cell. The company's technology promises to revolutionize biomedical research, just as genome sequencing once did. This chart shows profitability forecasts for the life sciences sector, reflecting investor confidence that proteomics will be the next big breakthrough.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Dna&v=1772647445713 "Graph of future (predicted) profits of companies in a market segment - Dna")
Future (predicted) profit of the market as a whole
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for large-scale protein analysis. This is a fundamental technology for biopharma. Corporate profit projections, as shown in this chart, influence the R&D budgets of large pharmaceutical companies, which are potential Nautilus clients, and their venture capital funding.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772647445764 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Nautilus Biotechnology
Nautilus Biotechnology is developing a platform for analyzing the proteome—the totality of all proteins in a cell—that promises to be orders of magnitude more powerful than existing technologies. The company has no revenue. The chart shows investors' high expectations for its ability to revolutionize biology and medicine by opening new ways to diagnose and treat diseases.
P/S market segment - Dna
Nautilus Biotechnology, Inc. is developing a proteome (protein assemblage) analysis platform designed to significantly accelerate and reduce the cost of protein analysis. Future revenue depends on the commercialization of the technology. This chart shows the average valuation in the sector, allowing one to assess how the market values Nautilus's breakthrough potential.
P/S of the market as a whole
Nautilus Biotechnology is developing a platform for analyzing the proteome—the sum of all proteins in the body—with unprecedented speed and scale. This could revolutionize biomedicine. This chart, showing average valuations, clearly demonstrates the gap between the valuations of companies with current sales and the value of scientific platforms with enormous long-term potential.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Nautilus Biotechnology
Nautilus Biotechnology is developing a proteome (protein assay) platform that could revolutionize biomedical research. This chart reflects investors' confidence in the future commercialization of this technology. The valuation is based on expected revenues from sales of the platform and consumables to scientific and pharmaceutical companies.
%20P%2FS%20Nautilus%20Biotechnology&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Nautilus-Biotechnology&v=1772647446083 "The graph of the company's future (projected) P/S Nautilus Biotechnology")
Future (projected) P/S of the market segment - Dna
Nautilus Biotechnology is developing a proteome (protein assemblage) analysis platform that promises to identify and measure proteins in samples with unprecedented speed and scale. The chart reflects investor expectations for Nautilus's future sales, demonstrating confidence in its potentially revolutionary technology for biomedical research.
%20P%2FS%20market%20segment%20graph%20-%20Dna&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Dna&v=1772647446113 "Future (projected) P/S market segment graph - Dna")
Future (projected) P/S of the market as a whole
Market sentiment regarding future revenue reflects faith in technological breakthroughs that will accelerate scientific research. Nautilus Biotechnology is developing a platform for protein analysis at an unprecedented scale. Their technology promises to revolutionize understanding biology and drug development, attracting investors betting on the tools of the future.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772647446122 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Nautilus Biotechnology
Nautilus Biotechnology is developing a revolutionary platform for protein analysis on an unprecedented scale. Being in the development stage, the company does not yet have a commercial product. Its financial curve reflects not sales revenue, but rather investments and research expenditures aimed at the future commercialization of this breakthrough technology.
Sales of companies in the market segment - Dna
Nautilus Biotechnology is developing a proteome (protein analysis) platform that promises to revolutionize biomedical research, just as sequencing has transformed genomics. This chart shows the total revenue in the DNA technology sector. It reflects the potential for the next step in biology—the detailed study of proteins, a field in which Nautilus is a pioneer.
Overall market sales
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for protein analysis at scale. The company's goal is to accelerate drug discovery and diagnostics. Its valuation is based on the potential of this breakthrough technology. This graph of the overall economic climate influences funding for fundamental research and innovative biotech platforms.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Nautilus Biotechnology
Nautilus Biotechnology aims to create a platform for proteome (protein assemblies) analysis that could revolutionize biomedical research. The company's future depends on the commercialization of this technology. The chart reflects speculative analyst forecasts, which are betting on the creation of a new standard in proteomics.
%20sales%20of%20the%20company%20Nautilus%20Biotechnology&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Nautilus-Biotechnology&v=1772647446346 "Schedule of future (projected) sales of the company Nautilus Biotechnology")
Future (projected) sales of companies in the market segment - Dna
Nautilus Biotechnology is developing a proteome (protein analysis) platform that could accelerate drug discovery and diagnostics. The company aims to revolutionize proteomics. This chart shows projected sales for the entire DNA technology segment and related areas, reflecting expected growth in the biomedical research market.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Dna&v=1772647446355 "Schedule of future (projected) sales of companies in the market segment - Dna")
Future (projected) sales of the market as a whole
Nautilus Biotechnology is developing a platform for proteome (protein assemblies) analysis, promising to revolutionize biomedical research. The company's success depends on the commercialization of its technology. This overall economic activity schedule influences R&D budgets at pharmaceutical and biotech companies, which are potential Nautilus clients.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772647446394 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Nautilus Biotechnology
Nautilus Biotechnology is developing a platform for large-scale proteome (protein assemblage) analysis. This metric reflects the financial realities of developing breakthrough technology. It demonstrates the R&D investment required to commercialize a platform that could revolutionize biomedical research.
Market segment marginality - Dna
Nautilus Biotechnology is developing a proteome (protein cluster) analysis platform that has the potential to revolutionize biomedical research. Profitability depends on the commercialization of this cutting-edge technology. This metric reflects the company's operational structure during the development of its innovative product.
Market marginality as a whole
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for protein analysis on an unprecedented scale. Their technology has the potential to accelerate drug development. While in the R&D stage, their valuation depends on achieving scientific goals. This overall profitability curve impacts their investors' willingness to fund long-term research projects.
Employees in the company, segment and market as a whole
Number of employees in the company Nautilus Biotechnology
Nautilus Biotechnology is developing a protein analysis (proteomics) platform that has the potential to revolutionize biomedical research. This chart shows the growth of its team of scientists and engineers. This increase is directly related to the intensity of R&D and investment in the development of this complex and breakthrough technology.
Share of the company's employees Nautilus Biotechnology within the market segment - Dna
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for protein analysis on an unprecedented scale. This graph shows the concentration of elite scientists and engineers at the intersection of biology, nanotechnology, and AI. The Nautilus team is shaping the future of analyzing the "molecules of life."
Number of employees in the market segment - Dna
Nautilus Biotechnology, Inc. aims to create a proteome (protein assemblage) analysis platform that will enable the measurement of proteins in the body with unprecedented accuracy and scale. This graph shows overall employment in the DNA and protein analysis sector. It illustrates the dawn of a new era in biology, where proteome analysis could become as important as genomics.
Number of employees in the market as a whole
Nautilus Biotechnology is creating a platform for proteome (protein) analysis, which could dramatically accelerate drug development. This breakthrough technology is at the intersection of biology, engineering, and IT. This graph shows the labor market where new industries are being born. Nautilus is creating demand for unique specialists capable of working with big data and complex biosystems.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Nautilus Biotechnology (NAUT)
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for protein analysis at scale. This chart reflects market expectations for this breakthrough technology. The astronomical market capitalization per employee demonstrates that investors believe in the platform's potential to transform science and medicine, and this belief drives the value, not the team's current performance.
%20of%20the%20company%20Nautilus%20Biotechnology%20(NAUT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Nautilus-Biotechnology-NAUT&v=1772647446800 "Chart of market capitalization per employee (in thousands of dollars) of the company Nautilus Biotechnology (NAUT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Dna
Nautilus Biotechnology is developing a platform for proteome (protein) analysis that could revolutionize biomedical research. It's a research-intensive company whose value lies in the potential of its technology. This metric demonstrates the enormous value the market places on their future breakthrough, measured per team member.
%20by%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Dna&v=1772647446851 "Market capitalization per employee (in thousands of dollars) by market segment - Dna")
Market capitalization per employee (in thousands of dollars) for the overall market
Nautilus Biotechnology aims to create a platform for protein analysis at an unprecedented scale. It's a deep tech company in the development stage. Its high market capitalization per employee reflects not current revenue, but rather investors' belief that its technology can revolutionize biomedical research and diagnostics, similar to DNA sequencing.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772647446892 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Nautilus Biotechnology (NAUT)
Nautilus Biotechnology is a life sciences company in development. They are developing a platform for complex protein analysis (proteomics). This is an in-depth R&D project requiring engineers, biologists, and programmers. This graph shows the net loss (investment) per employee working on this breakthrough technology.
%20Chart%20Nautilus%20Biotechnology%20(NAUT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Nautilus-Biotechnology-NAUT&v=1772647446946 "Company Profit Per Employee (in thousands of dollars) Chart Nautilus Biotechnology (NAUT)")
Profit per employee (in thousands of dollars) in the market segment - Dna
Nautilus Biotechnology is developing a protein analysis platform (proteomics). For a company bringing a new, complex technology to market, this metric is a future goal. The schedule sets the bar. NAUT's effectiveness will depend on how quickly the scientific community adopts their instruments and begins purchasing consumables, which will become the basis of their profits.
%20in%20the%20market%20segment%20-%20Dna&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Dna&v=1772647447049 "Chart of profit per employee (in thousands of dollars) in the market segment - Dna")
Profit per employee (in thousands of dollars) for the market as a whole
Nautilus Biotechnology (NAUT) is developing a platform for proteome (protein cluster) analysis, hoping to revolutionize biomedicine. Their R&D is highly ambitious and expensive. This reflects their status: the company burns through capital on research, and each scientist employed represents a major investment, not a source of profit.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772647447082 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Nautilus Biotechnology (NAUT)
For Nautilus Biotechnology, a company developing a protein analysis platform, this graph reflects the pre-commercial stage. Future revenue growth per employee will depend on the successful launch of its innovative technology, which promises to revolutionize biomedical research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Nautilus-Biotechnology-NAUT&v=1772647447144 "Sales chart per company employee Nautilus Biotechnology (NAUT)")
Sales per employee in the market segment - Dna
Nautilus Biotechnology is developing a platform for proteome (protein) analysis in individual cells, which should accelerate drug development. This is a deep R&D organization. This metric reflects the average revenue per employee for the segment. It demonstrates how productive their team of scientists and engineers is in commercializing this complex technology compared to competitors.
Sales per employee for the market as a whole
Nautilus Biotechnology (NAUT) is developing a platform for proteomics—large-scale protein analysis. It's an R&D company creating the "device of the future." This metric is an indicator of the future for NAUT. Zero values currently indicate the development stage. An increase in the graph will indicate that their complex platform is ready for commercialization and sale to laboratories.
Short shares by company, segment and market as a whole
Shares shorted by company Nautilus Biotechnology (NAUT)
Nautilus Biotechnology is a speculative company attempting to create a next-generation protein analysis (proteomics) platform. Like many "life science tool" companies, it has no revenue. This chart shows how many investors are betting that its ambitious technology won't work as advertised or that it won't compete with established methods.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Nautilus-Biotechnology-NAUT&v=1772647447276 "Short Shares Chart for the Company Nautilus Biotechnology (NAUT)")
Shares shorted by market segment - Dna
Nautilus Biotechnology (NAUT) is a company developing a platform for analyzing individual protein molecules, aiming to revolutionize proteomics. This chart shows the aggregate short position in the speculative scientific equipment sector, reflecting the immense skepticism of investors regarding the company's ability to commercialize its complex technology.
Shares shorted by the overall market
Nautilus (NAUT) is an R&D project in the field of proteomics. It's a "shovel" for biotech. When this chart shows rising fear, it signals a "venture winter." This means NAUT's clients (small biotechs) are freezing R&D and stopping buying its expensive, unproven equipment.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Nautilus Biotechnology (NAUT)
Nautilus (NAUT) is trying to create a "protein sequencer"—a proteomics analysis platform. It's one of the most speculative R&D bets in biotech. This chart measures the level of hype. It shows when euphoria about the technology's potential (overbought) or doubts (oversold) reach extremes.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Nautilus-Biotechnology-NAUT&v=1772647447360 "RSI 14 indicator chart for the company's stock Nautilus Biotechnology (NAUT)")
RSI 14 Market Segment - Dna
Nautilus (NAUT) is a "shovel" for biotech (proteomics). They (like Seer) are developing a "machine" that *automates* and *accelerates* protein analysis (but with *different* technology). The "Dna" sector (biotech/proteomics) thrives on R&D. RSI_14_Seg shows the "temperature" of the *entire* industry. It helps us understand: is NAUT's growth a niche or a general "hype"?
RSI 14 for the overall market
Nautilus Biotechnology (NAUT) is a biotech platform. This chart is an indicator of R&D health. In the euphoria of research, biotechs (NAUT's clients) are generously funded and launch hundreds of clinical trials using its platform. In the panic, R&D funding freezes, the number of trials drops, and demand for NAUT's services declines.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast NAUT (Nautilus Biotechnology)
Nautilus Biotechnology is developing a next-generation proteomics platform. Its goal is to create a technology for analyzing billions of individual protein molecules. This chart shows the speculative average price target from analysts, based on their belief in this breakthrough, but not yet commercialized, science.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-NAUT-Nautilus-Biotechnology&v=1772647447416 "A chart showing analyst consensus forecasts for the expected stock price. NAUT (Nautilus Biotechnology)")
The difference between the consensus estimate and the actual stock price NAUT (Nautilus Biotechnology)
Nautilus Biotechnology is a company aiming to revolutionize proteomics. It is developing a platform for analyzing millions of individual protein molecules. This chart shows the gap between the market valuation and analyst target price, highlighting the enormous, yet untapped, potential experts see in this technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-NAUT-Nautilus-Biotechnology&v=1772647447449 "A chart showing the difference between the consensus forecast and the actual stock price. NAUT (Nautilus Biotechnology)")
Analyst consensus forecast for stock prices by market segment - Dna
Nautilus (NAUT) is a biotech company developing a proteomics platform—a technology for analyzing thousands of proteins in a single cell. It's the "next step" after genomics. This chart shows general expectations for the DNA technology (and proteomics) sector. It reflects whether experts believe in this "R&D revolution."
Analysts' consensus forecast for the overall market share price
Nautilus Biotechnology is a biotech company developing a platform for proteomics—the analysis of proteins in the body, considered the next step beyond genomics. This chart shows overall risk appetite. For Nautilus, an early-stage company with a revolutionary but not yet commercialized technology, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Nautilus Biotechnology
Nautilus (NAUT) is a pre-revenue biotech company that doesn't offer treatments. Their specialty is proteomics: they're developing a futuristic platform for analyzing thousands of proteins in a cell (a competitor to Seer and Olink). This chart represents their R&D bet. Its valuation reflects the market's belief that their (very complex) technology will emerge from the lab and become the new NGS, but for proteins.
AKIMA Market Segment Index - Dna
Nautilus Biotechnology aims to revolutionize proteomics by creating a platform for measuring and analyzing proteins in the body with unprecedented accuracy. This chart shows the average index for the DNA technologies segment. It allows investors to assess how Nautilus, a company that sells shovels for science, is performing above or below the average.
The AKIM Index for the overall market
Nautilus Biotechnology is building a proteome (protein) analysis platform with the goal of revolutionizing biomedicine and drug discovery. This chart, reflecting the market average, provides context. It helps assess how this complex early-stage technology story compares to overall macroeconomic trends and R&D budgets.
